» Articles » PMID: 25220207

Tumor Budding in Colorectal Carcinoma Assessed by Cytokeratin Immunostaining and Budding Areas: Possible Involvement of C-Met

Overview
Journal Cancer Sci
Specialty Oncology
Date 2014 Sep 16
PMID 25220207
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor budding/sprouting has been shown to be an independent adverse prognostic factor in T1 and T3N0 colorectal carcinomas, however, its assessment could be improved by more accurate identification of budding carcinoma cells and consideration of budding areas. Moreover, tumor budding mechanisms are yet to be defined. In this study, we evaluated the identification of budding tumor cells by either H&E staining alone or H&E with immunohistochemistry and developed a scoring system based on budding grades and areas. We examined whether the budding score correlated with clinicopathologic features and prognosis and the association between tumor budding/sprouting and c-Met protein expression and phosphorylation and MET gene copy numbers because c-Met is known to play an important role in colorectal carcinoma tumorigenesis. Cytokeratin immunohistochemistry could identify tumors with shorter disease-free survival (DFS) from the low-grade budding group assessed with H&E alone. High budding scores based on budding grade and area were more significantly correlated with DFS than scores obtained using the budding grade alone. In tumors with a high budding score, c-Met expression and phosphorylation levels and MET gene copy numbers were significantly increased at the invasive front compared with those in superficial tumor portions. This study showed for the first time that high levels of phospho-c-Met at the invasive front were significantly associated with a high budding score and shorter DFS. In conclusion, a budding score assessed by budding grades and budding-positive areas correlates highly with clinicopathologic aggressive features of colorectal carcinoma.

Citing Articles

Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa.

Zeren S, Seker S, Akgun G, Okur E, Yerlikaya A Med Oncol. 2023; 40(10):298.

PMID: 37707637 DOI: 10.1007/s12032-023-02173-9.


Association between the expression levels of ADAMTS16 and BMP2 and tumor budding in hepatocellular carcinoma.

Jiang D, Xu S, Zhang C, Hu C, Li L, Zhang M Oncol Lett. 2023; 25(6):256.

PMID: 37205917 PMC: 10189853. DOI: 10.3892/ol.2023.13842.


Polyploid giant cancer cells and cancer progression.

Zhou X, Zhou M, Zheng M, Tian S, Yang X, Ning Y Front Cell Dev Biol. 2022; 10:1017588.

PMID: 36274852 PMC: 9581214. DOI: 10.3389/fcell.2022.1017588.


Tumor budding as a prognostic indicator in colorectal carcinoma: a retrospective study of primary colorectal carcinoma cases in a tertiary care center.

Shah A, Gami A, Desai N, Gandhi J, Trivedi P Indian J Surg Oncol. 2022; 13(3):459-467.

PMID: 36187533 PMC: 9515303. DOI: 10.1007/s13193-022-01498-7.


Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis.

Saxena K, Jolly M, Balamurugan K Transl Oncol. 2020; 13(11):100845.

PMID: 32781367 PMC: 7419667. DOI: 10.1016/j.tranon.2020.100845.


References
1.
Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C . Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008; 99(1):83-9. PMC: 2453041. DOI: 10.1038/sj.bjc.6604439. View

2.
Jedeszko C, Victor B, Podgorski I, Sloane B . Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 2009; 69(23):9148-55. PMC: 2789178. DOI: 10.1158/0008-5472.CAN-09-1043. View

3.
Losi L, Ponti G, Di Gregorio C, Marino M, Rossi G, Pedroni M . Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract. 2006; 202(9):663-70. DOI: 10.1016/j.prp.2006.05.003. View

4.
Zlobec I, Lugli A . Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2011; 1(7):651-61. PMC: 3248128. DOI: 10.18632/oncotarget.199. View

5.
Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y . Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer. 2011; 75(2):181-8. DOI: 10.1016/j.lungcan.2011.07.008. View